Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNausea after a Mounjaro injection typically begins within a few hours of the dose and, for most people, peaks during the first day or two. It usually eases within 48–72 hours as your body adjusts. This pattern (documented across the SURMOUNT clinical programme and reflected in the NHS tirzepatide guidance) tends to be most noticeable after your very first pen and after each dose increase. Mounjaro (tirzepatide) is a prescription-only medicine; a GPhC-registered prescriber must assess whether it is appropriate for you before any treatment begins. If you are already on treatment and nausea is making life difficult, keep reading — there are evidence-based reasons it happens and practical steps that genuinely help.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The SURMOUNT-1 trial, which followed more than 2,500 adults over 72 weeks and was published in the New England Journal of Medicine, recorded nausea as the most frequent adverse event across all tirzepatide dose groups. The pattern was consistent: nausea was most likely to occur in the first few days after a dose and was reported most frequently during the early weeks of treatment, particularly at the 2.5 mg starting phase and at each titration step upward.
What that means in practice is that the 24–48 hours after your weekly injection are the window of highest risk. For some people the discomfort is brief, a few hours of queasiness that passes before the next morning. For others it stretches closer to two days. By the third or fourth injection at the same dose, most people find the sensation has become noticeably lighter or has stopped altogether.
Dose increases reset the clock to some extent. When your prescriber moves you from, say, 5 mg to 7.5 mg, a fresh wave of mild nausea in the days that follow is entirely expected. This is the body recalibrating to a stronger signal from the dual GIP and GLP-1 receptors tirzepatide activates. The broader picture of when Mounjaro side effects start covers this titration pattern in more detail.
If nausea is severe, persistent beyond three or four days at a stable dose, or accompanied by sharp upper-abdominal pain that radiates to your back, contact a healthcare professional promptly. The MHRA's January 2026 Drug Safety Update flagged acute pancreatitis as a rare but serious possibility with GLP-1 medicines, severe, sustained stomach pain is the distinguishing symptom, and it warrants same-day assessment rather than watchful waiting.
Tirzepatide slows the rate at which food leaves your stomach, a property known as delayed gastric emptying. This is one of the mechanisms behind reduced appetite and, ultimately, weight loss. But the stomach is not used to content sitting there longer than usual, and the result is often a feeling of fullness that tips into nausea, particularly after eating.
The GLP-1 receptor, also activated by Mounjaro, has direct connections to the area of the brainstem that governs nausea and vomiting. Stimulating it produces appetite suppression, but it can also send a low-level nausea signal, especially at higher doses or early in treatment when the body has not yet adapted.
Understanding this is genuinely useful rather than just academic. Nausea is not a signal that the medicine is harming you; it is, in large part, the mechanism doing exactly what it was designed to do. Many people find that once they grasp this, the discomfort feels more manageable. That said, it is entirely valid to find it unpleasant, feeling sick every week is not something anyone should simply accept as inevitable, which is why practical adjustments matter so much.
For a detailed look at what else to expect during treatment, the full Mounjaro side effects guide covers the complete gastrointestinal profile, including less-discussed symptoms such as sulphur burps and watery diarrhoea.
There is no single fix that works for everyone, but a consistent set of adjustments emerged from patient experience reported across the SURMOUNT programme and echoed in clinical practice.
Injection timing. Some people find injecting in the evening means the worst of the nausea passes overnight, so it is less disruptive to the working day. Others prefer the morning so they can monitor how they feel. There is no clinically mandated time, consistency matters more than the hour, so pick whichever slot you are least likely to skip.
Eating strategy around injection day. Smaller portions, eaten slowly, reduce the burden on a stomach that is already emptying more slowly than usual. Fatty foods, heavily spiced meals and alcohol amplify nausea for most people on tirzepatide. Plain, protein-rich meals and adequate hydration are generally better tolerated. The guide on feeling sick after eating on Mounjaro goes further on this.
Staying upright after eating. Lying down shortly after a meal when gastric emptying is already delayed tends to worsen reflux and nausea. A short walk or simply sitting upright for an hour after eating can make a real difference.
What not to do. Skipping meals to avoid nausea tends to backfire, as an empty stomach is often more reactive to tirzepatide than a gently fed one. And never adjust your dose timing or skip an injection without speaking to your prescriber first, the titration schedule exists to build tolerance, not to be improvised around symptoms.
For context on what treatment involves more broadly, the Mounjaro overview page covers eligibility, the injection schedule and what to expect across the course of treatment. If you are considering starting and want to understand what the cost of private treatment typically involves, this price comparison guide is a useful reference.
Most nausea on tirzepatide is uncomfortable rather than dangerous, and it resolves. But some presentations need prompt attention.
Contact your prescriber if nausea is severe enough that you cannot keep food or fluids down for more than 24 hours, if you are showing signs of dehydration (dizziness, dark urine, infrequent urination), or if the discomfort is not improving after the first two weeks at a stable dose. These are not rare concerns; they are situations where a clinical conversation can lead to practical solutions, such as a slower titration or additional support.
Seek urgent medical help for severe stomach pain, particularly pain that starts centrally or in the upper abdomen and spreads toward the back. As the MHRA's Yellow Card reporting guidance notes, any suspected serious side effect should also be reported through the Yellow Card scheme, which helps regulators monitor medicines in real-world use.
If you are unsure whether what you are experiencing is within normal range, our prescribers at nume offer priority aftercare seven days a week, it is part of the service, not an extra. You can also get in touch directly if you have a specific question. For anyone earlier in their decision-making, our team is available to assess suitability through a free consultation, reviewed the same day by a real clinician.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.